Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoffmann, T. K.
Right arrow Articles by Whiteside, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoffmann, T. K.
Right arrow Articles by Whiteside, T. L.
Clinical Cancer Research Vol. 8, 2553-2562, August 2002
© 2002 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Spontaneous Apoptosis of Circulating T Lymphocytes in Patients with Head and Neck Cancer and Its Clinical Importance1

Thomas K. Hoffmann2, Grzegorz Dworacki2, Takashi Tsukihiro, Norbert Meidenbauer, William Gooding, Jonas T. Johnson and Theresa L. Whiteside3

University of Pittsburgh Cancer Institute [T. K. H., G. D., T. T., N. M., W. G., T. L. W.] and Departments of Pathology [T. L. W.] and Otolaryngology [J. T. J., T. L. W.], University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213

Spontaneous apoptosis was observed in a proportion of peripheralblood mononuclear cells obtained from patients withhead and neck cancer (HNC) but not from normal healthy donors (T. Saito et al., Clin. Cancer Res., 5: 1263–1273, 1999). To further investigate this phenomenon, peripheral blood mononuclear cells were obtained from patients with HNC or normal controls (NCs) and evaluated for expression of apoptosis markers (annexin V binding and caspase-3 activation), T-cell receptor-associated {zeta} chain, and the death receptor Fas (APO-1, CD95) in CD3+ T cells by multicolor flow cytometry. Soluble Fas ligand (sFasL) in the sera of these individuals was quantitated by ELISA. In patients with HNC, 74 ± 15% (mean ± SD) of CD3+ T cells were Fas+ compared with 52 ± 13% in NCs (P < 0.0001). Furthermore, 29 ± 16% of the Fas+ CD3+ T cells bound annexin V in patients and only 14% ± 7% of the Fas+ CD3+ T cells bound annexin V in NCs (P < 0.0001). In patients, Fas+ CD3+ cells preferentially underwent apoptosis and showed a loss of {zeta} chain expression. Significantly greater proportions of CD8+ T cells than CD4+ T cells were apoptotic (P < 0.0002), which indicates that CD8+ T cells were especially sensitive to apoptosis. Serum levels of sFasL were lower in HNC patients with active disease than in NCs or in patients with no evident disease (P < 0.0183). This suggested utilization of sFasL produced in vivo and activation of the Fas/Fas ligand (FasL) pathway in Fas+ T cells. Proportions of apoptotic T cells were higher in HNC patients than in NCs (P < 0.0001), and a subset of HNC patients with active disease had the highest proportions of circulating Fas+ annexin V+ T lymphocytes. The data indicate that the Fas/FasL pathway is involved in spontaneous apoptosis of circulating Fas+ T lymphocytes in cancer patients. Fas/FasL interactions might lead to excessive turnover of T cells in the circulation and, consequently, to reduced immune competence in patients with HNC.




This article has been cited by other articles:


Home page
Cancer Res.Home page
C. Badoual, G. Bouchaud, N. E. H. Agueznay, E. Mortier, S. Hans, A. Gey, F. Fernani, S. Peyrard, P. L. -Puig, P. Bruneval, et al.
The Soluble {alpha} Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer
Cancer Res., May 15, 2008; 68(10): 3907 - 3914.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Bhattacharyya, D. Mandal, B. Saha, G. S. Sen, T. Das, and G. Sa
Curcumin Prevents Tumor-induced T Cell Apoptosis through Stat-5a-mediated Bcl-2 Induction
J. Biol. Chem., June 1, 2007; 282(22): 15954 - 15964.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Kim, M. Emi, K. Tanabe, and K. Arihiro
Tumor-Driven Evolution of Immunosuppressive Networks during Malignant Progression
Cancer Res., June 1, 2006; 66(11): 5527 - 5536.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. E. Albers, C. Visus, T. Tsukishiro, R. L. Ferris, W. Gooding, T. L. Whiteside, and A. B. De Leo
Alterations in the T-Cell Receptor Variable {beta} Gene-Restricted Profile of CD8+ T Lymphocytes in the Peripheral Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., April 15, 2006; 12(8): 2394 - 2403.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. B. Frey and N. Monu
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response
J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Jewett, N. A. Cacalano, C. Head, and A. Teruel
Coengagement of CD16 and CD94 receptors mediates secretion of chemokines and induces apoptotic death of naive natural killer cells.
Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 1994 - 2003.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Badoual, S. Hans, J. Rodriguez, S. Peyrard, C. Klein, N. E. H. Agueznay, V. Mosseri, O. Laccourreye, P. Bruneval, W. H. Fridman, et al.
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
Clin. Cancer Res., January 15, 2006; 12(2): 465 - 472.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Parmiani, C. Castelli, and L. Rivoltini
Chemokine Receptor 7, A New Player in Regulating Apoptosis of CD8+ T Cells in Cancer Patients
Clin. Cancer Res., November 1, 2005; 11(21): 7587 - 7588.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-W. Kim, R. L. Ferris, and T. L. Whiteside
Chemokine C Receptor 7 Expression and Protection of Circulating CD8+ T Lymphocytes from Apoptosis
Clin. Cancer Res., November 1, 2005; 11(21): 7901 - 7910.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Timar, A. Ladanyi, C. Forster-Horvath, J. Lukits, B. Dome, E. Remenar, M. Godeny, M. Kasler, B. Bencsik, G. Repassy, et al.
Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma Modulates Intratumoral CD4/CD8 Ratio and Tumor Microenvironment: A Multicenter Phase II Clinical Trial
J. Clin. Oncol., May 20, 2005; 23(15): 3421 - 3432.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
M. S. Teng, M. S. Brandwein-Gensler, M. S. Teixeira, J. A. Martignetti, and D. C. Duffey
A Study of TRAIL Receptors in Squamous Cell Carcinoma of the Head and Neck
Arch Otolaryngol Head Neck Surg, May 1, 2005; 131(5): 407 - 412.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. W. Kim, E. Wieckowski, D. D. Taylor, T. E. Reichert, S. Watkins, and T. L. Whiteside
Fas Ligand-Positive Membranous Vesicles Isolated from Sera of Patients with Oral Cancer Induce Apoptosis of Activated T Lymphocytes
Clin. Cancer Res., February 1, 2005; 11(3): 1010 - 1020.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Wysocka, B. M. Benoit, S. Newton, L. Azzoni, L. J. Montaner, and A. H. Rook
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15
Blood, December 15, 2004; 104(13): 4142 - 4149.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
O. Bohana-Kashtan and C. I. Civin
Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance
Stem Cells, November 1, 2004; 22(6): 908 - 924.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Y. Shibuya, S. Kim, K. Nguyen, J. Do, C. E. McLaren, K.-T. Li, W.-P. Chen, P. Parikh, A. Wadhwa, X. Zi, et al.
Bioactive Suture: A Novel Immunotherapy for Head and Neck Cancer
Clin. Cancer Res., October 15, 2004; 10(20): 7088 - 7099.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-W. Kim, T. Tsukishiro, J. T. Johnson, and T. L. Whiteside
Expression of Pro- and Antiapoptotic Proteins in Circulating CD8+ T Cells of Patients with Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., August 1, 2004; 10(15): 5101 - 5110.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Kuss, B. Hathaway, R. L. Ferris, W. Gooding, and T. L. Whiteside
Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., June 1, 2004; 10(11): 3755 - 3762.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. M. Prins, F. Incardona, R. Lau, P. Lee, S. Claus, W. Zhang, K. L. Black, and C. J. Wheeler
Characterization of Defective CD4-CD8- T Cells in Murine Tumors Generated Independent of Antigen Specificity
J. Immunol., February 1, 2004; 172(3): 1602 - 1611.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. L. Whiteside, Y. Zhao, T. Tsukishiro, E. M. Elder, W. Gooding, and J. Baar
Enzyme-linked Immunospot, Cytokine Flow Cytometry, and Tetramers in the Detection of T-Cell Responses to a Dendritic Cell-based Multipeptide Vaccine in Patients with Melanoma
Clin. Cancer Res., February 1, 2003; 9(2): 641 - 649.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.